We are live on !
Find out more
Pfizer Portfolio holdings
AUM
$170M
Turnover
5.56%
1-Year Est. Return
191.09%
This Fund
S&P 500
This Quarter Est. Return
+54.78%
1 Year Est. Return
+191.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$437M
AUM Growth
-$139M
(-24%)
Cap. Flow
-$214M
Cap. Flow % of AUM
Cap. Flow %
-48.88%
Top 10 Holdings %
Top 10 Hldgs %
95.12%
Holding
21
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
0.8
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.7
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$214M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
BioNTech
BNTX
$21.6B
| $164M | 37.39% |
1,658,361
-2,000,000
| -55% | -$214M |
2024 Q4
3 quarters
|
|
2
Oric Pharmaceuticals
ORIC
$924M
| $64.5M | 14.75% |
5,376,344
| – | – |
2024 Q4
3 quarters
|
|
3
DELISTED
Tourmaline Bio
TRML
| $60.8M | 13.91% |
1,272,214
| – | – |
2024 Q4
3 quarters
|
|
4
Arvinas
ARVN
$453M
| $29.5M | 6.73% |
3,457,815
| – | – |
2024 Q4
3 quarters
|
|
5
Allogene Therapeutics
ALLO
$323M
| $27.3M | 6.25% |
22,032,040
| – | – |
2024 Q4
3 quarters
|
|
6
Celcuity
CELC
$3.28B
| $17.3M | 3.95% |
349,406
| – | – |
2024 Q4
3 quarters
|
|
7
Pyxis Oncology
PYXS
$195M
| $15.6M | 3.57% |
7,032,770
| – | – |
2024 Q4
3 quarters
|
|
8
Wave Life Sciences
WVE
$673M
| $13.7M | 3.14% |
1,875,000
| – | – |
2024 Q4
3 quarters
|
|
9
Zura Bio
ZURA
$136M
| $12.9M | 2.94% |
2,970,022
| – | – |
2024 Q4
3 quarters
|
|
10
Caribou Biosciences
CRBU
$44.3M
| $10.9M | 2.5% |
4,690,431
| – | – |
2024 Q4
3 quarters
|
|
11
Biohaven
BHVN
$2.28B
| $7.59M | 1.74% |
505,645
| – | – |
2024 Q4
3 quarters
|
|
12
Cardiff Oncology
CRDF
$61.8M
| $4.97M | 1.14% |
2,411,575
| – | – |
2024 Q4
3 quarters
|
|
13
Spero Therapeutics
SPRO
$58.8M
| $4.44M | 1.02% |
2,362,348
| – | – |
2024 Q4
3 quarters
|
|
14
Zentalis Pharmaceuticals
ZNTL
$170M
| $1.44M | 0.33% |
953,834
| – | – |
2024 Q4
3 quarters
|
|
15
NextCure
NXTC
$27.4M
| $924K | 0.21% |
157,646
| – | – |
2024 Q4
3 quarters
|
|
16
AN2 Therapeutics
ANTX
$164M
| $908K | 0.21% |
715,295
| – | – |
2024 Q4
3 quarters
|
|
17
Q32 Bio
QTTB
$279M
| $550K | 0.13% |
277,777
| – | – |
2024 Q4
3 quarters
|
|
18
DELISTED
ESSA Pharma
EPIX
| $320K | 0.07% |
1,675,000
| – | – |
2024 Q4
3 quarters
|
|
19
Bolt Biotherapeutics
BOLT
$14.8M
| $167K | 0.04% |
31,305
| – | – |
2024 Q4
3 quarters
|
|
20
Ginkgo Bioworks
DNA
$809M
| $42.7K | 0.01% |
2,928
| – | – |
2024 Q4
3 quarters
|
|
21
Senseonics Holdings Inc
SENS
$530M
| $18.9K | ﹤0.01% |
2,171
| – | – |
2024 Q4
3 quarters
|
|
Similar funds
PP
Pfizer's Q3 2025 Portfolio in Review
As of Q3 2025, Pfizer held 21 positions worth $437M, down 24% from $576M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Pfizer withdrew a net $214M in Q3 2025, reducing 1 holding. Its largest reduction was BioNTech, cutting an estimated $214M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Pfizer's biggest Q3 2025 reduction was BioNTech, cutting an estimated $214M.
- Pfizer's ten largest holdings make up 95% of its $437M portfolio in Q3 2025.
- Pfizer opened 0 new positions and closed 0 in Q3 2025.
- Pfizer's portfolio value fell 24% quarter-over-quarter to $437M.
Based on Pfizer's 13F filing for Q3 2025, filed 13 Nov 2025.